Clinical Trial Update: Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab alone or with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma has completed. Sponsor: Tianjin Me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Resectable Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED